United States · Platforms & data · Benzinga
FDA Clears Teva's Newly Acquired At-Home Agitation Treatment in Schizophrenia and Bipolar Disorder

Detailed summary
Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) announced on Monday that the U.S. Food and Drug Administration (FDA) approved IGALMI (dexmedetomidine) sublingual film for at-home…
MarketNews shows the headline and summary published by the outlet. The full article is on the publisher's website. (www.benzinga.com)




